SLS Surges in Retail Interest as REGAL Trial Data Nears

SLS ranked No. 2 by score on Tendie.bot after a 3-position jump, driven by 7 posts and strong engagement.
Discussion centered on the REGAL trial's event-driven unblinding at 80 events, now expected in Q1 2026, with top-line data projected for spring.
Acquisition speculation — particularly involving Merck — added a second layer of upside narrative alongside the primary trial catalyst.

Why SLS Caught Fire on Reddit

SELLAS Life Sciences Group

$SLS vaulted to the No. 2 spot in Tendie.bot's daily stock rankings on January 3, 2026, up three positions from the prior session. The jump came on the back of seven posts — concentrated heavily in r/10xPennyStocks — that collectively drew 341 comments, 1,137 upvotes, and an overwhelmingly bullish net sentiment of 0.6375.

Unlike many penny-stock pump-and-dump patterns, the

$SLS discussion on Friday was anchored by a well-understood binary catalyst: the REGAL Phase 3 trial for galinpepimut-S in acute myeloid leukemia.

SLS

The REGAL Trial Timeline Is Front and Center

Reddit users in r/10xPennyStocks drilled into specific details from the company's most recent update. The REGAL trial is event-driven — unblinding kicks off when 80 deaths are recorded. As of December 26, 2025, 72 events had occurred. The company noted in its year-end update that the pace of event accumulation had slowed because patients were surviving longer than modeled, a detail many retail investors interpreted as a bullish signal.

Based on the current rate, the 80th event is expected in Q1 2026. After data cleaning and statistical analysis, top-line results are projected for the spring — roughly March through May. The concentrated time frame gives the stock a defined catalyst window, and retail traders are positioning accordingly.

Acquisition Talk Adds to the Narrative

A prominent post on r/10xPennyStocks walked through a detailed valuation model that mapped out potential acquisition scenarios involving Merck

$MRK. The author argued that if REGAL succeeds, SELLAS would transition from a speculative biotech name to a pharmaceutical asset with a de-risked late-stage pipeline, making it an attractive buyout target. The post assigned specific per-share takeover values depending on how clean the data readout is, adding an explicit price-target layer to the conversation.

This dual narrative — a high-impact binary catalyst plus a defined M&A backstop — helps explain the unusually detailed, analytical tone of the discussion. The sentiment was strongly positive, but the posts were grounded in clinical-trial mechanics rather than hype alone.

Community Sentiment and Position-Sizing Questions

Not every thread was purely bullish. One top-voted post asked directly whether it was too late to hop in on

$SLS, with the original poster weighing a potential pullback to $4 before entering. The 79-comment thread reflected genuine debate about entry timing and risk management, a sign that the audience was engaged but not blindly chasing momentum.

Another thread focused on multi-ticker plays for the week ahead, naming

$SLS alongside other names like

$SIDU,

$SMX, and

$ALT. The diversity of picks suggests that while

$SLS was the biggest single-story stock of the day, it was part of a broader appetite for high-risk, catalyst-driven small caps.

No same-day news articles were ingested for

$SLS on January 3, meaning the volume and depth of Reddit discussion were driven almost entirely by the community parsing existing company disclosures and trial timelines rather than reacting to a fresh press cycle.

Subscribe to Tendie.bot for more market recaps.